Therapy: Lenvatinib and radioiodine-refractory thyroid cancers Journal Article

   

Authors:	Dunn, L.; Fagin, J. A.
Article Title:	Therapy: Lenvatinib and radioiodine-refractory thyroid cancers
Keywords:	overall survival; sorafenib; cancer growth; drug efficacy; liver cell carcinoma; drug approval; progression free survival; quality of life; tumor volume; food and drug administration; kidney carcinoma; radioactive iodine; aflibercept; short survey; ras protein; thyroid cancer; immunosurveillance; tumor vascularization; antiangiogenic activity; b raf kinase; phase 3 clinical trial (topic); lenvatinib; human; priority journal
Journal Title:	Nature Reviews Endocrinology
Volume:	11
Issue:	6
ISSN:	1759-5029
Publisher:	Nature Publishing Group
Date Published:	2015-06-01
Start Page:	325
End Page:	327
Language:	English
DOI:	10.1038/nrendo.2015.53
PROVIDER:	scopus
PUBMED:	25824678
PMCID:	PMC4518863
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-84929960380&partnerID=40&md5=b624aee14f6d8c1bc5f18c3d9737f634
Notes:	Export Date: 2 July 2015 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/74992